Dr. Zheng Hu is an Associate Professor and Deputy Director at the Translational Medicine Institute of South China University, based at The First People’s Hospital of Chenzhou, Hunan, China. With a Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences, his research focuses on gene editing technology, cancer biomarkers, and screening of anti-tumor compounds from traditional Chinese herbs. He has made significant contributions to cancer screening and nucleic acid detection, with several publications in high-impact journals. Dr. Hu is also recognized for his work on CRISPR-based detection systems and molecular pathogenesis in various cancers.
Professional Profile:
Orcid
Summary of Suitability:
Dr. Zheng Hu is an outstanding candidate for the Best Researcher Award due to his prolific research contributions, particularly in gene editing and cancer biomarker development. His innovative approach to applying cutting-edge technologies like CRISPR in clinical settings, along with his strong publication record and leadership, makes him highly deserving of recognition. His research has the potential to revolutionize cancer diagnostics and treatments, underscoring his impact in the biomedical field.
🎓Education:
Dr. Zheng Hu earned his Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in Beijing, China, between 2011 and 2014. Prior to that, he completed his M.S. in Genetics from Xiangya Medical School of Central South University in Changsha, China, from 2001 to 2005. He also holds a B.S. in Biology, which he obtained from the School of Life Science at Central China Normal University in Wuhan, China, during 1994 to 1998.
🏢Work Experience:
Dr. Zheng Hu has held the position of Associate Professor at the Translational Medicine Institute of South China University, located at The First People’s Hospital of Chenzhou, Hunan, China, since 2018. Prior to this role, he worked as a Postdoctoral Research Fellow at Xiangya Hospital, Central South University, in Changsha, from 2015 to 2018. Between 2014 and 2015, Dr. Hu served as an Assistant Investigator at the same institute where he is now a professor. He also worked as an Assistant Investigator at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, from 2010 to 2011, and as a Research Associate at the same institute from 2005 to 2010. Earlier in his career, between 1998 and 2001, he was a Technician and Teaching Assistant at Xiangya Medical School of Central South University in Changsha.
🏅Awards and Honors:
Dr. Zheng Hu is recognized for his significant contributions to the development of CRISPR-based detection systems and cancer biomarker research. He has published extensively in high-impact journals, earning recognition for his advancements in cancer screening and gene editing technology. His work has greatly influenced the fields of translational medicine and molecular biology, showcasing innovative approaches to cancer detection and treatment.
Publication Top Notes:
-
Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells
-
Rapid, portable Epstein‒Barr virus DNA detection using enzymatic recombinase amplification combined with the CRISPR–Cas12a system
-
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma
-
SARS-CoV-2 and Its Omicron Variants Detection with RT-RPA-CRISPR/Cas13a-Based Method at Room Temperature
-
Stabilization of UCA1 by N6-methyladenosine RNA methylation modification promotes colorectal cancer progression